ES3048233T3 - Methods for wound healing - Google Patents

Methods for wound healing

Info

Publication number
ES3048233T3
ES3048233T3 ES20161504T ES20161504T ES3048233T3 ES 3048233 T3 ES3048233 T3 ES 3048233T3 ES 20161504 T ES20161504 T ES 20161504T ES 20161504 T ES20161504 T ES 20161504T ES 3048233 T3 ES3048233 T3 ES 3048233T3
Authority
ES
Spain
Prior art keywords
methods
wound healing
healing
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20161504T
Other languages
English (en)
Spanish (es)
Inventor
Mia Phillipson
Evelina Vågesjö
Stefan Roos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ilya Pharma AB
Original Assignee
Ilya Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilya Pharma AB filed Critical Ilya Pharma AB
Application granted granted Critical
Publication of ES3048233T3 publication Critical patent/ES3048233T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES20161504T 2014-12-23 2015-12-23 Methods for wound healing Active ES3048233T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1451658 2014-12-23

Publications (1)

Publication Number Publication Date
ES3048233T3 true ES3048233T3 (en) 2025-12-09

Family

ID=55080095

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20161504T Active ES3048233T3 (en) 2014-12-23 2015-12-23 Methods for wound healing
ES15822941T Active ES2864373T3 (es) 2014-12-23 2015-12-23 Métodos para la cicatrización

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15822941T Active ES2864373T3 (es) 2014-12-23 2015-12-23 Métodos para la cicatrización

Country Status (9)

Country Link
US (3) US10696974B2 (enExample)
EP (2) EP3735979B1 (enExample)
JP (2) JP6581208B2 (enExample)
KR (2) KR102297619B1 (enExample)
CN (2) CN107208107B (enExample)
AU (2) AU2015370982B2 (enExample)
CA (1) CA2971520C (enExample)
ES (2) ES3048233T3 (enExample)
WO (1) WO2016102660A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3408378B1 (en) 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
BR112019007812A2 (pt) * 2016-10-31 2019-07-16 Kimberly Clark Co métodos para arquivar e de recriar um microbioma.
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途
CN117487686A (zh) * 2018-07-24 2024-02-02 生命大地女神有限公司 选择和使用褪黑素支持细菌以减少婴儿绞痛
MX2020014222A (es) * 2018-07-24 2021-03-09 Biogaia Ab Metodos terapeuticos que utilizan cepas bacterianas las cuales son capaces de aumentar los niveles de adenosina.
CN109112155A (zh) * 2018-08-02 2019-01-01 南昌大学 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用
CN109517772A (zh) * 2018-10-30 2019-03-26 南昌大学 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用
CN109234298A (zh) * 2018-10-30 2019-01-18 南昌大学 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
US20230310522A1 (en) * 2019-06-24 2023-10-05 Mendes S.R.L. Composition with antibacterial and re-epithelializing action including probiotics
CN110623792B (zh) * 2019-09-23 2022-05-06 温州医科大学附属第一医院 一种医学敷料及其制备方法
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
CA3228922A1 (en) 2021-10-11 2023-04-20 Ajinomoto Co., Inc. Bacterium modified to express heterologous tat protein
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins
AU2022429649A1 (en) * 2021-12-29 2024-08-08 Ilya Pharma Ab Treatment of therapy-induced enteropathy
KR102752056B1 (ko) * 2023-07-12 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물
GB202405882D0 (en) 2024-04-26 2024-06-12 Ilya Pharma Ab Treatment of mdr infections
CN118948906B (zh) * 2024-10-16 2025-02-14 温州医科大学附属第一医院 一种促进创面愈合的乳酸杆菌生物膜衍生物及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1998035035A1 (fr) * 1997-02-07 1998-08-13 Shionogi & Co., Ltd. Nouveau recepteur de chimiokine cxc murin
AU781679B2 (en) 1999-07-05 2005-06-09 Intrexon Actobiotics Nv Delivery of trefoil peptides
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
WO2006018446A2 (en) 2004-08-20 2006-02-23 Actogenix Nv Method to improve lactococcus preservation
ES2626610T3 (es) 2005-08-30 2017-07-25 Intrexon Actobiotics Nv Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
US20080254014A1 (en) 2005-10-03 2008-10-16 Actogenix N V Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20110183348A1 (en) 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
RU2008147398A (ru) 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
CA2672229A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
CA2673409A1 (en) 2006-12-19 2009-06-26 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
RU2009127718A (ru) 2006-12-19 2011-01-27 Ферросан А/С (Dk) Раневой или тканевой перевязочный материал, содержащий молочнокислые бактерии
EP3124614B1 (en) 2007-01-12 2022-06-08 Intrexon Actobiotics NV Lactococcus promoters and uses thereof
EP2774621B1 (en) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
WO2008155120A2 (en) 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
US8435953B2 (en) 2007-11-07 2013-05-07 Yasuhiko Tabata Sustained release composition containing SDF-1
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
US8367109B2 (en) 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
EP2344626B1 (en) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
US20100143305A1 (en) * 2008-12-08 2010-06-10 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
WO2010123699A2 (en) 2009-04-21 2010-10-28 University Of Miami Compositions, kits and methods for promoting ischemic and diabetic wound healing
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
WO2010124855A1 (en) 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
US20100310514A1 (en) * 2009-06-04 2010-12-09 Chi Hin Cho Anti-Inflammatory Bacteria
CL2009001506A1 (es) 2009-07-01 2009-09-25 Univ Concepcion Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
US20120283315A1 (en) 2009-08-28 2012-11-08 Penn Marc S Sdf-1 delivery for treating ischemic tissue
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN101985052B (zh) 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
DK2704704T3 (en) 2011-05-03 2019-01-14 Dupont Nutrition Biosci Aps PROBIOTIC BACTERIES FOR TOPICAL TREATMENT OF SKIN DISORDERS
US9920324B2 (en) 2011-06-01 2018-03-20 Intrexon Actobiotics Nv Polycistronic expression system for bacteria
EP2758512B1 (en) 2011-09-23 2018-05-09 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
BR112014006883A8 (pt) 2011-09-23 2018-06-26 Actogenix Nv bactéria gram-positiva não patogênica carecendo de atividade do componente llc do sistema pts celobiose específico (ptcc), medicamento, aditivo alimentar, composição probiótica, ou cultura iniciadora, produto alimentar e métodos
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
CN105263507A (zh) 2013-03-15 2016-01-20 尤文塔斯医疗公司 使用sdf-1减轻瘢痕形成
WO2014146202A1 (en) * 2013-03-18 2014-09-25 London Health Sciences Centre Research Inc. Bacteria for the prevention, treatment and diagnosis of breast cancer
HUE059749T2 (hu) 2013-04-29 2022-12-28 Medregen Llc Sebgyógyítás autológ õssejt-mobilizáció útján
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction

Also Published As

Publication number Publication date
WO2016102660A1 (en) 2016-06-30
US20230093013A1 (en) 2023-03-23
US20200299703A1 (en) 2020-09-24
AU2019204290A1 (en) 2019-07-04
JP2020005646A (ja) 2020-01-16
KR20170097194A (ko) 2017-08-25
AU2015370982B2 (en) 2019-03-21
CA2971520A1 (en) 2016-06-30
CN107208107A8 (zh) 2017-12-26
CN107208107B (zh) 2021-07-09
EP3237622A1 (en) 2017-11-01
EP3237622B1 (en) 2021-02-24
ES2864373T3 (es) 2021-10-13
JP6581208B2 (ja) 2019-09-25
CN107208107A (zh) 2017-09-26
KR20200020994A (ko) 2020-02-26
EP3735979A1 (en) 2020-11-11
US11473091B2 (en) 2022-10-18
CN113403244A (zh) 2021-09-17
US20180187202A1 (en) 2018-07-05
KR102081493B1 (ko) 2020-02-26
JP7033109B2 (ja) 2022-03-09
EP3735979B1 (en) 2025-08-13
CA2971520C (en) 2024-04-09
KR102297619B1 (ko) 2021-09-02
EP3735979C0 (en) 2025-08-13
AU2015370982A1 (en) 2017-07-13
CN113403244B (zh) 2022-08-19
AU2019204290B2 (en) 2021-12-16
JP2018502600A (ja) 2018-02-01
US10696974B2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
ES3048233T3 (en) Methods for wound healing
ZA201608536B (en) Wound dressing
ZA201604261B (en) Wound treatment apparatuses
GB201405284D0 (en) Wound dressing
IL248856A0 (en) New treatment
IL251493A0 (en) Device for dressing a wound
GB2530640B (en) Wound dressing
GB201418565D0 (en) Wound dressing
GB201514024D0 (en) Wound Dressing
GB201504698D0 (en) Wound dressing
GB201504693D0 (en) Wound dressing
PL3119445T3 (pl) Opatrunek na rany
PL4035635T3 (pl) Opatrunek na ranę
GB201512582D0 (en) Wound treatment
GB201420862D0 (en) Wound dressing
GB2525658B (en) Improved wound dressing
GB2526115B (en) Wound dressing
GB201509795D0 (en) Wound healing
GB201408549D0 (en) Wound dressing
GB201418134D0 (en) Bandage
GB201516895D0 (en) Wound treatment
GB201513506D0 (en) Wound treatment
GB201413797D0 (en) Healing concept
GB201417719D0 (en) New treatment
GB201418826D0 (en) Minecraft theatre